Overview

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
Aim of study is to collect long term safety and tolerability data on enteric-coated mycophenolate sodium with regard to adverse events, serious adverse events, and patient and graft survival. After successful completion of study CERL080A301 study, patients who previously were on enteric-coated mycophenolate sodium or MMF were given opportunity to remain on enteric-coated mycophenolate sodium or convert from MMF to enteric-coated mycophenolate sodium.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Mycophenolate mofetil
Mycophenolic Acid